Clinical trials: Colorectal Cancer Metastatic to Liver
Metastatic Colorectal Cancer
FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer
PURPOSE: A primary aim of phase II FOCULM study is to explore whether cetuximab in combination with FOLFOXIRI as first treatment could improve surgical conversion in patients with KRAS/NRAS wild-type, unresectable liver - only…
- Trial name
- FOCULM (NCT02063529)
- Testing
- FOLFOXIRI + Cetuximab, FOLFOXIRI
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
Nelitolimod is a classC toll-like receptor 9 (TLR9) agonist that binds to TLR9 receptors on myeloid-derived suppressor cells(MDSCs) and helps reshape the tumor microenvironment (TME) and promote antitumor immunity.
- Trial name
- NCT07172282
- Testing
- Nelitolimod
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Colorectal Cancer Metastatic
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
The goal of this clinical trial is to learn whether the combination of balstilimab, botensilimab, and agenT-797 is safe and effective in treating adults with previously treated metastatic colorectal cancer that is microsatellite…
- Trial name
- NCT07550088
- Testing
- Balstilimab (BAL), Botensilimab (BOT), agenT-797
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Darren Sigal, MD
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer Metastatic
Raman Spectroscopy for Liver Tumours Following Liver Surgery
The aim of the proposed research is to develop a quick and reliable method for automated evaluation of tissue sections for residual tumour in histology specimens following liver surgery.
- Trial name
- NCT05995990
- Testing
- Raman Spectrometry
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Cancer Metastatic to the Liver, Hepatocellular Carcinoma
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not…
- Conditions
- Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma
- Trial name
- NCT00986661
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 5 sites in United States
- Volunteers
- 78 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Colorectal Cancer, Islet Cell Tumor
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer
- Trial name
- NCT00019786
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colon Cancer, Rectal Cancer
Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
This is a phase I dose escalation study (3+3 design) with a dose expansion arm (12 patients) designed to evaluate safety of the combination of Tas-102 and radioembolization using Yttrium-90 (90Y) resin microspheres for patients…
- Conditions
- Colon Cancer, Rectal Cancer, Liver Metastases
- Trial name
- NCT02602327
- Testing
- Tas-102, SIR-Sphere
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer, Liver Metastases
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
HARVEST is an investigator-initiated prospective randomized controlled study comparing adjuvant intravenous systemic chemotherapy with or without HAI- floxuridine (FUDR) in CRC patients post-liver metastasectomy.
- Conditions
- Colorectal Cancer, Liver Metastases, HAI
- Trial name
- NCT03500874
- Testing
- FUDR, Oxaliplatin, Leucovorin
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-sen University
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
This phase 0 trial is studying whether 2 weeks of cetuximab and dasatinib will change tumor cells in patients with colorectal cancer and liver metastases that can be removed by surgery.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT00835679
- Testing
- cetuximab, dasatinib, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Adenocarcinoma Metastatic in the Liver
Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases
This is a single-center, open-label, exploratory phase II trial to evaluate efficacy and safety of Retlirafusp alfa (PD-L1/TGF-βRII bispecific fusion protein) combined with standard first-line targeted-chemotherapy as conversion…
- Trial name
- NCT07815288
- Testing
- Retlirafusp alfa Combined with Targeted Therapy and Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colon Cancer Liver Metastasis
Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases
The purpose of this study was a randomized controlled trial to compare the effect of oxaliplatin and raltitrexed treatment of colorectal cancer with liver metastases by TACE hepatic artery infusion
- Trial name
- NCT02557490
- Testing
- oxaliplatin and raltitrexed
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhu Xu
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Colon Cancer, Rectum Cancer
The Value of Laparoscopic Ultrasound in Patients Undergoing Laparoscopic Resection for Cancer of the Colon or Rectum
The following project deals with a Danish multicenter trial that evaluates the value of Laparoscopic Ultrasound examination (LUS) in laparoscopic surgery for colon and rectum cancer (CRC).
- Conditions
- Colon Cancer, Rectum Cancer, Liver Metastases
- Trial name
- NCT02079389
- Testing
- Lap+Lus
- Where
- 4 sites in Denmark
- Volunteers
- 280 people
- Sponsor
- Odense University Hospital
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic